Butterfly Network (BFLY) Earnings Date & Reports

Key Takeaways

• Butterfly Network reported third quarter 2026 revenue of $32.6 million, up 52% year over year and about 9% above the top end of its own guidance.
• GAAP (Generally Accepted Accounting Principles) net loss narrowed to $12.8 million, or $0.05 per share, compared with a $34.0 million loss, or $0.13 per share, a year earlier.
• The company posted its highest gross margin in its history at 73.0%, while adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss improved to just $1.2 million.
• Butterfly raised its full-year 2026 revenue guidance to $123 million to $126 million, representing roughly 26% to 29% growth.
• Butterfly Embedded revenue surged more than 1,000% to $11.1 million, driven by the Midjourney partnership and new partners including Merge Labs and Bridge Neurotech.
• Shares rose about 5.8% on the day of the report as investors reacted to the beat and raised outlook.
• For more on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore our dedicated pages.
• Discover new trading ideas by exploring our Trending AI Robots.

Earnings Context and Why It Matters

Butterfly Network, a pioneer in semiconductor-based ultrasound devices, cloud software, and artificial intelligence, has been transitioning from a hardware-first point-of-care ultrasound company into a broader platform play anchored by enterprise software and high-growth "Embedded" partnerships. The third quarter of 2026 was a pivotal checkpoint for this strategy, as investors looked for evidence that recent revenue acceleration and margin expansion could be sustained. Prior quarters had shown strong gains in U.S. revenue and narrowing losses, but the Core POCUS (point-of-care ultrasound) business had grown more modestly. This report mattered because it tested whether the company's Embedded pipeline and enterprise momentum could offset international softness and keep Butterfly on track toward its profitability goals.

Reported Results

Butterfly Network reported third quarter 2026 revenue of $32.6 million, a 52% increase from $21.5 million a year earlier and ahead of the roughly $28.4 million consensus estimate. Net loss was $12.8 million, or $0.05 per share, versus a $34.0 million loss, or $0.13 per share, in the prior-year period. Adjusted (non-GAAP) loss per share came in at about $0.01, better than the roughly $0.04 loss analysts had projected.

Gross margin reached a record 73.0%, up 913 basis points year over year, helped by a higher mix of Embedded revenue. Adjusted EBITDA loss narrowed to $1.2 million, an 85% improvement from $8.1 million a year earlier. U.S. revenue climbed 71% to $27.5 million, while international revenue declined 5% to $5.1 million amid deal timing shifts. Core POCUS revenue rose 5% to $21.5 million, while Embedded revenue jumped over 1,000% to $11.1 million. Cash and equivalents stood at $122.3 million at quarter end.

Management raised full-year 2026 revenue guidance to $123 million to $126 million and issued fourth-quarter revenue guidance of $31 million to $34 million, with an adjusted EBITDA loss of $3 million to $6 million. The company also highlighted five seven-figure and ten six-figure TCV (total contract value) enterprise deals.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. Whether you are monitoring earnings movers like Butterfly Network or scanning for new setups across sectors, the AI Screener can help you narrow the field with speed and precision.

Market Reaction and Investor Sentiment

Investors responded favorably to the report, pushing shares up roughly 5.8% on the day to close near $7.81. The combination of a revenue beat, a record gross margin, a sharply narrower adjusted EBITDA loss, and a full-year guidance raise helped refresh sentiment after a period of choppier short-term trading. The market's positive tone was tempered somewhat by the fourth-quarter guidance range, which implied a potential sequential revenue dip, and by the disclosure of a new $150 million shelf registration and ATM (at-the-market) program, which some investors view as a potential dilution risk. Still, the dominant interpretation was that Butterfly's Embedded strategy is scaling faster than expected while the enterprise pivot continues to firm up the Core business.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Butterfly can sustain its Embedded momentum while stabilizing international results. Management signaled expectations for improved fourth-quarter and 2027 performance, but Embedded revenue remains lumpy because it is tied to partner program timing and development milestones. Concentration risk around a few large partners, including Midjourney, is another factor to monitor, particularly since management does not break out individual partner contributions.

On the Core side, the company's enterprise strategy is gaining traction through multi-year contracts and Compass AI adoption. The FedRAMP (Federal Risk and Authorization Management Program) authorization achieved during the quarter opens access to the federal government, the largest healthcare purchaser, and management pointed to a growing pipeline. The Home & Community Care program has moved into execution, with initial revenue expected in the fourth quarter and more meaningful contribution anticipated by 2028.

Key variables to track in coming quarters include gross margin durability, cash burn, the pace of international recovery, and whether enterprise deals layer into a steadier revenue base. The new shelf registration and ATM program also bear watching, as any equity issuance could affect share count. As always, these items should be evaluated alongside broader demand for portable, AI-enabled ultrasound across hospital, clinic, and out-of-hospital settings.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations